Press Room

Continuous Manufacturing Forum

Start
Monday, September 16, 2024 - 09:00
End
Thursday, September 19, 2024 - 18:00
Location: New Jersey, United States
Continuous Manufacturing Forum takes place in Princeton NJ, September 16-19. Register today

Register now -听

The advancements of Continuous Tableting (CT) are sparking a growing interest and driving insightful discussions among academia, the pharmaceutical industry, CDMOs, and equipment providers. This September 四色AV experts and esteemed professionals from Merck, GEA, Pfizer, ThermoFisher, Vertex, Graz University, and others will join The Continuous Manufacturing Forum (CMF) in Princeton NJ, to embark on a journey to explore innovative solutions, delve into promising technological breakthroughs, and gain firsthand insights into how industry experts are seamlessly integrating CT in drug product development.

In this event, we embark on a journey to explore innovative solutions, delve into promising technological breakthroughs, and gain firsthand insights into how industry leaders are seamlessly integrating continuous manufacturing in small molecule drug development.听The forum will feature engaging presentations, interactive workshops, and insightful panel discussions.听

Don't miss this opportunity to connect with academia, the pharmaceutical industry, CDMOs, and equipment providers, and visit 四色AV's CT facilities in New Jersey accompanied by our team.听

Join the conference's sessions led by our experts in Continuous Tableting

"Perspectives on the 10-Year Horizon of Continuous Manufacturing"

Chaired by our expert Sarang Oka, the session will听focus on the long-term evolution of CM / Continuous Tableting, featuring perspectives from academia, industry innovators, and CDMOs.听

Description: The aim of the session is to look inside a hypothetical crystal ball and discuss the long-term evolution of continuous manufacturing (tableting). This is facilitated by hearing perspectives from thought-leaders on how they see the technology evolve in the medium to long term. The perspective building exercise is meant to be holistic with inputs from academia, innovators and the CDMO space and provided by experts and practitioners with meaningful, extensive first-hand experience in the technology. The session concludes with an interactive panel discussion that is meant to inspire and challenge our thinking of the evolution of the technology.

"Effective Release: Applications of Control Methods and PAT's Future"

Anthony Tantuccio will lead a discussion into the agility of CM in Oral Solid Dose (OSD) processes, highlighting Real-Time Release testing (RTRt) as a crucial element.听

Description:听There has been a general expectation that applying continuous manufacturing (CM) to oral solid dose (OSD) processes increases manufacturing agility. This is achieved by enabling just-in-time manufacturing and flexible batch sizes, ultimately reducing long cycles times. However, when reducing manufacturing cycle time, batch release cycle time should not become the bottleneck, therefore, an effective and equally agile release strategy should be considered.听
Real Time Release testing (RTRt) can be more appropriate for CM OSD than traditional analytical release, as the later is expected to be a bottleneck and drive the batch release cadence. Spectroscopic methods have emerged as the primary process analytic technology (PAT) tool to enable RTRt due to synergies when monitoring the process dynamics. However, building, deploying, and maintaining PAT methods can result in significant overhead and CMC complexity. This session is meant to highlight some of the successes and challenges leading industrial adopters have employed to manage the balance of PAT utility vs employment of other real time methods to support RTRt.

Sarang Oka
Anthony Tantuccio

Sarang Oka

Production Senior Manager
Drug Product Continuous Manufacturing

Anthony Tantuccio

听Fellow of Continuous Tableting at 四色AV

Learn more about and register for the听听today.

You might be interested in:

The Future is Continuous

Meet our experts and find out if Continuous Tableting is right for your product.

  • Webinar - for the most comprehensive three-part webinar series about Continuous Tableting (CT) for drug product. 四色AV will be joining experts from Merck, Vertex Pharmaceuticals and GEA Group to present the "Opportunities, Challenges and Success in Implementing Continuous Tableting 鈥 From R&D to Commercial Manufacturing".
  • Scientific Article - Read our latest scientific article about Continuous Tableting - 鈥淐ontinuous Tableting and the Road to Global Adoption

and find out how we can support your project.

schedule a meeting

Also in the Press Room

See All

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024